Patent License Agreement Sample Contracts

Aridis Pharmaceuticals, Inc. – PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENTEXCLUSIVE and NON-EXCLUSIVE COVER PAGE (July 18th, 2018)

This Patent License Agreement, hereinafter referred to as the Agreement, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) and/or Patent Application(s)), Appendix B (Fields of Use and Territory and Biological Materials and Documentation), Appendix C (Royalties), Appendix D (Modifications), Appendix E (Benchmarks), Appendix F (Commercial Development Plan) and Appendix G (Plan for Developing Countries). The Parties to this Agreement are:

Unimin Corp – Patent License Agreement (June 6th, 2018)

THIS PATENT LICENSE AGREEMENT (License Agreement) is effective as of the 1st day of June, 2018 (the Effective Date), by and between: Covia Holdings Corporation, a Delaware Corporation, having a business address at 258 Elm Street, New Canaan, CT 06840 (hereinafter Licensor); and SCR-Sibelco N.V., a corporation of Belgium, having a business address at Plantin Moretuslei 1A Antwerp Belgium B-2018 (hereinafter Licensee).

Unimin Corp – Patent License Agreement (June 6th, 2018)

THIS PATENT LICENSE AGREEMENT (License Agreement) is effective as of the 1st day of June, 2018 (the Effective Date), by and between: Covia Holdings Corporation, a Delaware Corporation, having a business address at 258 Elm Street, New Canaan, CT 06840 (hereinafter Licensor); and SCR-Sibelco N.V., a corporation of Belgium, having a business address at Plantin Moretuslei 1A Antwerp Belgium B-2018 (hereinafter Licensee).

Unimin Corp – Patent License Agreement (June 6th, 2018)

THIS PATENT LICENSE AGREEMENT (License Agreement) is effective as of the 1st day of June, 2018 (the Effective Date), by and between: Covia Holdings Corporation, a Delaware Corporation, having a business address at 258 Elm Street, New Canaan, CT 06840 (hereinafter Licensor); and SCR-Sibelco N.V., a corporation of Belgium, having a business address at Plantin Moretuslei 1A Antwerp Belgium B-2018 (hereinafter Licensee).

Unimin Corp – Patent License Agreement (June 6th, 2018)

THIS PATENT LICENSE AGREEMENT (License Agreement) is effective as of the 1st day of June, 2018 (the Effective Date), by and between: Covia Holdings Corporation, a Delaware Corporation, having a business address at 258 Elm Street, New Canaan, CT 06840 (hereinafter Licensor); and SCR-Sibelco N.V., a corporation of Belgium, having a business address at Plantin Moretuslei 1A Antwerp Belgium B-2018 (hereinafter Licensee).

Unimin Corp – Patent License Agreement (June 6th, 2018)

THIS PATENT LICENSE AGREEMENT (License Agreement) is effective as of the 1st day of June, 2018 (the Effective Date), by and between: Covia Holdings Corporation, a Delaware Corporation, having a business address at 258 Elm Street, New Canaan, CT 06840 (hereinafter Licensor); and SCR-Sibelco N.V., a corporation of Belgium, having a business address at Plantin Moretuslei 1A Antwerp Belgium B-2018 (hereinafter Licensee).

Unimin Corp – Patent License Agreement (June 6th, 2018)

June, 2018 (the Effective Date), by and between: Covia Holdings Corporation, a Delaware Corporation, having a business address at 258 Elm Street, New Canaan, CT 06840 (hereinafter Licensor); and SCR-Sibelco N.V., a corporation of Belgium, having a business address at Plantin Moretuslei 1A Antwerp Belgium B-2018 (hereinafter Licensee).

Universal Display Corporation – Oled Patent License Agreement (May 3rd, 2018)

THIS OLED PATENT LICENSE AGREEMENT (this "Agreement") is entered into effective as of January 1, 2018 (the "Effective Date"), by and between Samsung Display Co., Ltd. ("SDC"), an entity incorporated under the laws of the Republic of Korea and having a place of business at 1 Samsung-ro, Giheung-gu, Yongin-si, Gyeonggi-do, 17113, Korea, and Universal Display Corporation ("Universal Display"), an entity incorporated under the laws of the Commonwealth of Pennsylvania, U.S.A. and having a place of business at 375 Phillips Boulevard, Ewing, New Jersey 08618, U.S.A.

Evelo Biosciences, Inc. – Confidential Treatment Requested Evelo Biosciences, Inc. MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH PATENT LICENSE AGREEMENT (April 30th, 2018)

This patent license agreement (Agreement) is by and between Mayo Foundation for Medical Education and Research, a Minnesota charitable corporation, located at 200 First Street SW, Rochester, Minnesota 55905-0001 (MAYO), and Evelo Biosciences, Inc. (COMPANY), a Delaware corporation, having a place of business at 620 Memorial Drive, Suite 200 West, Cambridge, Massachusetts 02139, each a Party, and collectively Parties.

Aridis Pharmaceuticals, Inc. – PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENTEXCLUSIVE and NON-EXCLUSIVE COVER PAGE (April 20th, 2018)

This Patent License Agreement, hereinafter referred to as the Agreement, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) and/or Patent Application(s)), Appendix B (Fields of Use and Territory and Biological Materials and Documentation), Appendix C (Royalties), Appendix D (Modifications), Appendix E (Benchmarks), Appendix F (Commercial Development Plan) and Appendix G (Plan for Developing Countries). The Parties to this Agreement are:

Regent Technologies Inc – Regent - Solar Logic Patent License Agreement First Amendment (April 17th, 2018)

This FIRST AMENDMENT ("Amendment") of the PATENT LICENSE AGREEMENT ("Agreement") is entered into and made effective as of July 1, 2017 ("Effective Date"), by and among REGENT TECHNOLOGIES, INC., organized under the laws of the State of Texas having offices at 5646 Milton Street, #722, Dallas, Texas 75206 ("Licensor"), and SOLAR LOGIC INCORPORATED, organized and existing under the laws of the Texas (USA), having its offices at 801 North Maple Street, Muenster, Texas 76252 ("SLI") ("Licensee") (the parties herein sometimes referred to individually a "Party" or collectively as "Parties").

Evelo Biosciences, Inc. – Confidential Treatment Requested Evelo Biosciences, Inc. MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH PATENT LICENSE AGREEMENT (April 13th, 2018)

This patent license agreement (Agreement) is by and between Mayo Foundation for Medical Education and Research, a Minnesota charitable corporation, located at 200 First Street SW, Rochester, Minnesota 55905-0001 (MAYO), and Evelo Biosciences, Inc. (COMPANY), a Delaware corporation, having a place of business at 620 Memorial Drive, Suite 200 West, Cambridge, Massachusetts 02139, each a Party, and collectively Parties.

Evelo Biosciences, Inc. – Confidential Treatment Requested Evelo Biosciences, Inc. MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH PATENT LICENSE AGREEMENT (March 21st, 2018)

This patent license agreement (Agreement) is by and between Mayo Foundation for Medical Education and Research, a Minnesota charitable corporation, located at 200 First Street SW, Rochester, Minnesota 55905-0001 (MAYO), and Evelo Biosciences, Inc. (COMPANY), a Delaware corporation, having a place of business at 620 Memorial Drive, Suite 200 West, Cambridge, Massachusetts 02139, each a Party, and collectively Parties.

Aeglea BioTherapeutics, Inc. – Amended and Restated Patent License Agreement Agreement No. PM1401501 (March 13th, 2018)

This Amended and Restated Patent License Agreement ("Patent License Agreement") is between the Licensor and the Licensee identified below (collectively, "Parties", or singly, "Party").

Kura Oncology, Inc. – RE: Research Agreement Between Kura Oncology, Inc. ("Kura") and the Regents of the University of Michigan (The "University") Dated February 15, 2015 (The "Research Agreement") (Amendment 6 to the Patent License Agreement Dated December 22, 2014) (March 12th, 2018)

Pursuant to Section 8.2 of the Research Agreement, we hereby give notice of the exercise by Kura of its option to obtain an exclusive royalty-bearing license to the University's interest in the patent application numbered [...***...]. Effective upon this notice, the Patent License Agreement between the University and Kura is deemed amended (Amendment 6) to add the above-referenced patent application to subsection (ii)(a) of the definition of PATENT RIGHTS under such agreement.

La Jolla Pharmaceutical Company – CONFIDENTIAL THE GEORGE WASHINGTON UNIVERSITY Amended and Restated Patent License Agreement (February 22nd, 2018)

This Amended and Restated Patent License Agreement (this "Agreement") is made by and between the George Washington University, a congressionally chartered not-for-profit corporation ("University") located in the District of Columbia, and La Jolla Pharmaceutical Company, a California corporation ("Company"). This Agreement is being signed on March 1, 2016 (the "Execution Date"). This Agreement will become effective as of March 1, 2016 (the "Effective Date").

Securetech, Inc. – Patent License Agreement (February 16th, 2018)

This Patent License Agreement ("Agreement") is made by and between Securetech, Inc., a Wyoming corporation ("Licensee"), Lee Kao and Thao Kao, Minnesota residents (collectively, "Inventor"), and Shongkawh, LLC, a Minnesota limited liability company ("Assignee"); (collectively, "Parties").

Solid Biosciences, LLC – Patent License Agreement (January 16th, 2018)

This Agreement is effective as of March 10, 2016 (the EFFECTIVE DATE), between Solid GT, LLC (LICENSEE) having the address in Article 12 below, and the Regents of the University of Michigan, a constitutional corporation of the state of Michigan (MICHIGAN) having the address in Article 12 below. LICENSEE and MICHIGAN hereby agree as follows:

Solid Biosciences, LLC – First Amendment to Patent License Agreement (January 16th, 2018)

This First Amendment to Patent License Agreement (this FIRST AMENDMENT), effective as of the date set forth above the signatures of the parties below (the AMENDMENT EFFECTIVE DATE), is by and between Solid GT, LLC (LICENSEE) and the Regents of the University of Michigan, a constitutional corporation of the state of Michigan (MICHIGAN), and amends that certain Patent License Agreement between MICHIGAN and LICENSEE dated as of March 10, 2016 (the LICENSE AGREEMENT). Capitalized terms used herein without definition shall have the meaning given such terms in the LICENSE AGREEMENT.

Solid Biosciences, LLC – Patent License Agreement (December 29th, 2017)

This Agreement is effective as of March 10, 2016 (the EFFECTIVE DATE), between Solid GT, LLC (LICENSEE) having the address in Article 12 below, and the Regents of the University of Michigan, a constitutional corporation of the state of Michigan (MICHIGAN) having the address in Article 12 below. LICENSEE and MICHIGAN hereby agree as follows:

Brooklyn Cheesecake & Dessrt – Exclusive Commercial Patent License Agreement (November 9th, 2017)

This Exclusive Commercial Patent License Agreement (this "Agreement") is between American Science and Technology Corporation, an Illinois corporation ("Licensor"), Ali Manesh, a resident of Illinois ("Principal") and Meridian Innovations, LLC, a Georgia limited liability company ("Licensee").

Erytech Pharma – Public Health Service Patent License Agreement Exclusive Cover Page (October 6th, 2017)

This Patent License Agreement, hereinafter referred to as the Agreement, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options). The Parties to this Agreement are:

Appliance Recycling Centers of America, Inc. – Patent License Agreement (August 21st, 2017)

THIS PATENT LICENSE AGREEMENT (this "'PLA") is made and entered into as of August 14, 2017 (the "Effective Date") by and between Appliance Recycling Centers of America, Inc. ("Licensor''), a Minnesota corporation with a principal place of business in Minneapolis, Minnesota, and Recleim PA, LLC ("Licensee"), a Delaware limited liability company with a principal place of business in Atlanta, Georgia Licensor and Licensee are referred to herein collectively as the "Parties" and each individually as a "Party".

Kura Oncology, Inc. – Fifth Amendment to Patent License Agreement (August 7th, 2017)

This FIFTH AMENDMENT TO PATENT LICENSE AGREEMENT ("Amendment") is entered into as of May 24, 2017 (the "Amendment Effective Date") by and between Kura Oncology, Inc. ("Licensee") having the address set forth in Article 12 of the Agreement (as defined below), and the Regents of the University of Michigan, a constitutional corporation of the state of Michigan ("Michigan").

Solid Biosciences, LLC – Patent License Agreement (August 4th, 2017)

This Agreement is effective as of March 10, 2016 (the EFFECTIVE DATE), between Solid GT, LLC (LICENSEE) having the address in Article 12 below, and the Regents of the University of Michigan, a constitutional corporation of the state of Michigan (MICHIGAN) having the address in Article 12 below. LICENSEE and MICHIGAN hereby agree as follows:

Zlato Inc. – Patent License Agreement (July 14th, 2017)

THIS AGREEMENT (hereinafter referred to as the "Agreement") is made by and between Pharma GP ApS (hereinafter referred to as "Licensor"), a corporation with principal offices at Fabriksvej 48, 4700 Naestved, Denmark, and Vilacto Bio Inc, a limited company with principal offices at The Seagram Building, 375 Park Avenue Suite 2607, New York City NY 10152 U.S.A., (hereinafter referred to as "Licensee").

Dipexium Pharmaceuticals, Inc. – Amended and Restated Patent License Agreement Between the Board of Regents of the University of Texas System and Plx Pharma Inc. Dated December 11, 2009 (June 12th, 2017)

THIS AGREEMENT ("Agreement") is between the Board of Regents ("Board") of The University of Texas System ("System"), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of The University of Texas Health Science Center at Houston ("UTHSC-H"), a component institution of System and PLx Pharma Inc., a Texas corporation ("PLx"), with its principal place of business at 8285 El Rio, Suite 130, Houston, Texas 77054. Board, UTHSC-H, and PLx may individually be referred to as Party or collectively as the Parties.

Ab International Group Corp. – Patent License Agreement (June 6th, 2017)

GUANGZHOU SHENGSHITUHUA FILM AND TELEVISON COMPANY LIMITED, a company incorporated in China and having and address at 2nd Floor, 45 Hollywood Road, Hong Kong (the "Licensor")

Selecta Biosciences Inc – Patent License Agreement - Exclusive (May 11th, 2017)

This Patent License Agreement, hereinafter referred to as the "Agreement", consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options).

uniQure B.V. – Public Health Service Patent License Agreement - Nonexclusive Cover Page (May 9th, 2017)

This Patent License Agreement, hereinafter referred to as the Agreement, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D ((Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options). The Parties to this Agreement are:

uniQure B.V. – PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT - EXCLUSIVE and NON-EXCLUSIVE COVER PAGE (May 9th, 2017)
argenx N.V – Certain Confidential Portions of This Exhibit Were Omitted and Replaced With [...***...]. A Complete Version of This Exhibit Has Been Filed Separately With the Secretary of the U.S. Securities and Exchange Commission Pursuant to an Application Requesting Confidential Treatment Pursuant to Rule 406 Under the Securities Act of 1933, as Amended. Patent License Agreement (April 21st, 2017)

This Patent License Agreement (Agreement) is between The Board of Regents of The University of Texas System, an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of The University of Texas Southwestern Medical Center, a component institution of The University of Texas System (Licensor) and arGEN-X BV, a Dutch corporation, with its principal place of business at Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands (Licensee) (collectively, Parties, or singly, Party).

argenx N.V – Certain Confidential Portions of This Exhibit Were Omitted and Replaced With [...***...]. A Complete Version of This Exhibit Has Been Filed Separately With the Secretary of the U.S. Securities and Exchange Commission Pursuant to an Application Requesting Confidential Treatment Pursuant to Rule 406 Under the Securities Act of 1933, as Amended. Patent License Agreement (April 5th, 2017)

This Patent License Agreement (Agreement) is between The Board of Regents of The University of Texas System, an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of The University of Texas Southwestern Medical Center, a component institution of The University of Texas System (Licensor) and arGEN-X BV, a Dutch corporation, with its principal place of business at Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands (Licensee) (collectively, Parties, or singly, Party).

Document Security Systems, Inc. – Patent License Agreement (March 28th, 2017)

As of the EFFECTIVE DATE, Document Security Systems, Inc. (hereinafter "DSS") having a place of business at 200 Canal View Blvd., Suite 300, Rochester, NY 14623, and Intellectual Discovery Co. Ltd. (hereinafter "ID"), a Korean corporation, having an address at 10 Golden Tower Bldg. #511 Samseong-ro, Gangnam-gu, Seoul, 06158 Korea. DSS and ID (each individually, a "Party", and collectively, the "Parties") hereby agree as follows:

Aeglea BioTherapeutics, Inc. – Amended and Restated Patent License Agreement Agreement No. PM1401501 (March 23rd, 2017)

This Amended and Restated Patent License Agreement ("Patent License Agreement") is between the Licensor and the Licensee identified below (collectively, "Parties", or singly, "Party").